Oreon Life Science is a medical-focused company that has grown primarily in the medical aesthetics field since its establishment in 2008. The company plans, develops, and manufactures a wide range of aesthetic solutions—including hyaluronic acid (HA) fillers, biostimulators, and skin boosters—building integrated manufacturing capabilities that cover the entire process from R&D to production. Based on its in-house production facility and corporate research institute located in Seongnam, Oreon Life Science operates a production system that meets global quality standards, including ISO 13485 certification, medical device manufacturing licenses, and GMP approval, while continuously strengthening its technological competitiveness through sustained R&D.
Key products include the iLEAD® filler series and the i·NOVA and i·JUV skin booster lines, each of which has secured competitiveness in the global aesthetic market based on clinical stability and functional performance. In particular, in 2026 the company plans to introduce new next-generation aesthetic solutions such as collagen fillers, CaHA-based fillers, and NAD-related products, pursuing both portfolio expansion and technological advancement.
Oreon Life Science has focused its business on overseas markets, accumulating performance in the global medical aesthetics sector. The company has exported products primarily to countries with high demand for medical aesthetics, including the Middle East (UAE, Saudi Arabia, Iraq, and Jordan) and Latin America (Brazil and Chile), and has established collaborative relationships with local distributors and specialized medical aesthetic distributors in each market. Through this export-oriented strategy, Oreon Life Science products are currently supplied to more than 80 countries worldwide, maintaining stable distribution performance across diverse market environments.
Through its participation in KIMES 2026, Oreon Life Science plans to comprehensively present its product competitiveness and manufacturing capabilities required by the global medical aesthetics market, while sharing its technological response strategies to evolving industry trends. As the medical aesthetics industry rapidly shifts away from volume-focused procedures toward next-generation materials emphasizing safety, durability, and biocompatibility, the importance of manufacturers’ R&D capabilities and quality management systems continues to grow.
At KIMES 2026, Oreon Life Science will showcase its flagship aesthetic technology with the iLEAD® Body Filler as a core product, alongside an aesthetic portfolio comprising CaHA-based fillers, collagen fillers, and NAD⁺-based solutions. The iLEAD® Body Filler is a large-volume HA filler developed for body contouring, designed to achieve stable volume formation and uniform tissue distribution. It is engineered to maintain material stability even in large-volume treatment environments, with emphasis on procedural handling and consistency of results.
The accompanying CaHA-based filler is designed based on a mechanism that provides structural support while stimulating collagen production. CaHA particles function as a scaffold within tissue and promote collagen generation through fibroblast activation, aiming not only for short-term volume enhancement but also for long-term tissue improvement.
The collagen filler focuses on improving tissue density and restoring skin elasticity, with a biocompatible formulation designed to support natural tissue response and stable longevity. In addition, the NAD⁺-based solution is structured for use in post-procedure skin condition management and integrated aesthetic approaches, based on the role of NAD⁺ in cellular energy metabolism and recovery.
Together, these products form an integrated portfolio that supports a stepwise aesthetic solution—from volume formation to tissue environment improvement and ongoing skin condition management. Each product has undergone internal testing, including material property evaluations and stability assessments, to verify function and quality, continuously building technical credibility aligned with global market requirements.
Oreon Life Science has identified Europe, the Middle East, and South America as core target markets for overseas business expansion. Europe places strong emphasis on medical device quality and manufacturing reliability, and the company plans to pursue stable market entry through collaboration with specialized medical device distributors and aesthetic distribution partners. In the Middle East, where demand for high-value aesthetic procedures continues to rise, Oreon Life Science intends to expand partnerships with local distributors and hospital and clinic networks, focusing on the UAE and Saudi Arabia. South America is a rapidly growing region driven by the popularization of aesthetic procedures, and the company is pursuing phased collaborations centered on Brazil and Chile.
Looking ahead, Oreon Life Science has positioned R&D-driven portfolio advancement and overseas market expansion as its core strategic priorities in order to proactively respond to technological directions and product trends demanded by the global medical aesthetics market. In the short term, the company plans to establish a next-generation aesthetic solution lineup centered on collagen fillers, CaHA-based fillers, and NAD⁺-related products scheduled for release in 2026, while gradually expanding application areas and clinical use cases for each product.
Meanwhile, through participation in KIMES 2026, Oreon Life Science plans to engage in in-depth business discussions with overseas buyers and distribution partners, laying the foundation for mid- to long-term collaboration to support sustainable growth in global markets.